JPH06104620B2 - Skin cosmetics - Google Patents

Skin cosmetics

Info

Publication number
JPH06104620B2
JPH06104620B2 JP62176904A JP17690487A JPH06104620B2 JP H06104620 B2 JPH06104620 B2 JP H06104620B2 JP 62176904 A JP62176904 A JP 62176904A JP 17690487 A JP17690487 A JP 17690487A JP H06104620 B2 JPH06104620 B2 JP H06104620B2
Authority
JP
Japan
Prior art keywords
skin
molecular weight
salts
effect
test
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP62176904A
Other languages
Japanese (ja)
Other versions
JPS6422809A (en
Inventor
達 宮本
良一 内田
Original Assignee
鐘紡株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 鐘紡株式会社 filed Critical 鐘紡株式会社
Priority to JP62176904A priority Critical patent/JPH06104620B2/en
Publication of JPS6422809A publication Critical patent/JPS6422809A/en
Publication of JPH06104620B2 publication Critical patent/JPH06104620B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/08Anti-ageing preparations
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/68Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73Polysaccharides
    • A61K8/735Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Cosmetics (AREA)

Description

【発明の詳細な説明】 (技術分野) 本発明は、老化防止効果(荒肌改善効果、角質改善効
果、保湿効果等)と美肌効果に優れた皮膚化粧料に関す
る。
TECHNICAL FIELD The present invention relates to a skin cosmetic having excellent anti-aging effects (rough skin improving effect, keratin improving effect, moisturizing effect, etc.) and beautiful skin effect.

(従来技術) 従来より、乾燥した老化皮膚を改善する為に、皮膚に適
度な水分と油分を与える親水性の皮膚保湿剤と油性の皮
膚柔軟剤とを皮膚化粧料に配合することが知られてい
る。しかしながらグリセリン、プロピレングリコール等
の皮膚保湿剤は皮膚の最外層である角質層の水分を吸収
して、かえって皮膚の水分を損失する原因となることが
ある。また、流動パラフィン、ワセリン等の皮膚柔軟剤
は、表皮からの水分蒸散を充分に防ぐ程度に皮膚化粧料
に含有せしめる時には、皮膚の正常な新陳代謝を阻害
し、またべとつくなどの違和感を与えるなど、必ずしも
満足出来るものではなかった。
(Prior Art) Conventionally, in order to improve dry and aged skin, it has been known to blend a hydrophilic skin moisturizer and an oily emollient which give appropriate moisture and oil content to the skin cosmetics. ing. However, skin moisturizers such as glycerin and propylene glycol may absorb water in the stratum corneum, which is the outermost layer of the skin, and may cause water loss on the contrary. In addition, liquid softeners such as liquid paraffin and petrolatum inhibit the normal metabolism of the skin when it is contained in the skin cosmetics to the extent that water evaporation from the epidermis is sufficiently prevented, and give a feeling of strangeness such as stickiness. It was not always satisfactory.

即ち、これらの配合剤の物理的作用による表皮への水分
補強あるいは表皮よりの水分蒸散防止では、皮膚の水分
保持機能を亢進するまでには至らなかった。
That is, the reinforcement of water in the epidermis or the prevention of water transpiration from the epidermis by the physical action of these compounding agents has not been able to enhance the water retention function of the skin.

近年では、特開昭61−260008号公報、特開昭61−271205
号公報などに記載の如く、皮膚を始めとする生体組織中
に存在することが知られているセラミド類の化粧料への
応用が提案されているが、これらの成分を単独で配合し
てなる皮膚化粧料を、皮膚に適用したとしても皮膚の水
分保持機能を亢進させることは未だ充分ではない。
In recent years, JP-A-61-260008 and JP-A-61-271205
As described in Japanese Patent Publication, application of ceramides, which are known to exist in living tissues such as skin, to cosmetics has been proposed, but these ingredients are blended alone. Even if a skin cosmetic is applied to the skin, it is still insufficient to enhance the water retention function of the skin.

また、ヒアルロン酸を始めとする酸性ムコ多糖類は、特
公昭33−500号公報、特公昭51−11178号公報、特開昭54
−52733号公報にみられるように保湿剤として皮膚化粧
料の成分として応用されているが、酸性ムコ多糖類単独
では皮膚の表面の水分量を調節するのみであり、皮膚内
部の水分保持機能を亢進し、美肌効果を発現する程には
至らなかった。
Further, acidic mucopolysaccharides such as hyaluronic acid are disclosed in JP-B-33-500, JP-B-51-11178, and JP-A-54-54.
Although it has been applied as a moisturizing agent as a component of skin cosmetics as seen in Japanese Patent Publication No. 52733/1993, acidic mucopolysaccharides alone only regulate the amount of water on the surface of the skin, and have a function of retaining water inside the skin. It did not reach the level where it was promoted and a beautiful skin effect was exhibited.

(発明の開示) そこで、本発明者等は、上述の現状に鑑み、鋭意研究を
重ねた結果、セラミド、グルコシルセラミド、ガラクト
シルセラミドの群より選択された少なくとも一種と、低
分子量の酸性ムコ多糖類及びその塩の群より選択された
少なくとも一種とを配合した皮膚化粧料は、本発明が目
的としている老化防止効果(荒肌改善効果、角質改善効
果、保湿効果等)と美肌効果を顕著に発現することを見
出し、本発明を完成するに至った。
(Disclosure of the Invention) Therefore, the present inventors, in view of the above-mentioned current situation, as a result of intensive studies, at least one selected from the group of ceramide, glucosylceramide, and galactosylceramide, and a low-molecular-weight acidic mucopolysaccharide. And a skin cosmetic containing at least one selected from the group of salts thereof remarkably exhibits the antiaging effect (rough skin improving effect, keratin improving effect, moisturizing effect, etc.) and beautiful skin effect which are the objects of the present invention. The present invention has been completed and the present invention has been completed.

皮膚の水分は、真皮から表皮の基底細胞層、更に角質層
へと外層に向うにつれて減少する水分含量の勾配に沿っ
て、常に皮膚内部から外層部へ移動し、角質層を通じて
外部へ蒸散しているが、この水分蒸散は主に顆粒層頂部
の層板顆粒から角質層に及び緻密な細胞組織からなる防
御機能(バリヤー機能)により制御されており、該蒸散
量(不感蒸泄値、以下TWL値と略記する)は例えば健常
な皮膚の正常な状態における前腕部皮表では0.2〜0.3mg
/cm2/hrの範囲であり、通常は0.25mg/cm2/hr程度以下に
保持されている。これに対して、通常にみられる乾燥皮
膚(ドライスキン)あるいは老化皮膚にみられる乾燥皮
膚では、その程度に応じてTWL値は上記の範囲の上限値
もしくはそれより大きな値を示し、皮膚の水分保持機能
が低下していることが認められる。これはそれら乾燥皮
膚の場合、角質層の防御機能による通常の制御限界を超
えた状態にあるか、あるいは該防御機能が衰えているこ
とに由来するものである。
Skin water constantly moves from the inside of the skin to the outer layer along the gradient of the water content that decreases from the dermis to the basal cell layer of the epidermis and further to the stratum corneum toward the outer layer, and transpires to the outside through the stratum corneum. However, this water transpiration is controlled mainly by the defense function (barrier function) composed of dense cell tissues from the lamina granules at the top of the granule layer to the stratum corneum. (Abbreviated as value) is, for example, 0.2 to 0.3 mg for the forearm skin surface in the normal state of healthy skin.
It is in the range of / cm 2 / hr, and is usually maintained at about 0.25 mg / cm 2 / hr or less. On the other hand, in normal dry skin (dry skin) or dry skin found in aged skin, the TWL value shows the upper limit of the above range or a higher value depending on the degree, and It is recognized that the retention function is deteriorated. This is because, in the case of those dry skins, the normal control limit by the defense function of the stratum corneum has been exceeded, or the defense function has deteriorated.

従って、角質層及び層板顆粒の組織を緻密化し、その防
御機能を賦活することができれば、これによって皮膚の
水分保持機能が亢進され、皮膚は健常な状態に保持され
ると共に、更に乾燥皮膚の改善ないしは修復が可能とな
るのである。
Therefore, if the tissues of the stratum corneum and lamellar granules are densified and their defense function can be activated, the water retention function of the skin is enhanced by this, and the skin is maintained in a healthy state, and further dry skin It can be improved or repaired.

そこで、本発明者等は、セラミド、グルコシルセラミ
ド、ガラクトシルセラミド並びに低分子量の酸性ム多糖
類及びその塩のヒト皮膚に対する作用効果に関して鋭意
研究した結果、後記特定のこれらのセラミッド類と低分
子量の酸性ムコ多糖類及び/又はその塩類を、化粧料基
剤中に同時に配合し、皮膚に適用した時には、皮膚の表
面及び皮膚の最外層である角質層に強い親和性を示し、
それらの構造を緻密化し、老化皮膚を改善する作用を有
することを見出した。また、低分子の酸性ムコ多糖類及
びその塩類は皮膚の表面及び皮膚の最外層でる角質層に
強い親和性を示すとともに低分子物質であることによ
り、角質層内部に浸透し、皮膚内部の水分機能を調節
し、皮膚の保湿機能を亢進させる機能を発揮するもので
ある。本発明の皮膚化粧料は、皮膚それ自体の水分保持
機能を亢進することにより、乾燥皮膚を改善し、あるい
は皮膚を健常な状態に保持してその老化を防ぎ、皮膚に
湿潤性(しっとり感)、柔軟性(滑らか感)、弾力性及
び艶を与える美肌効果を有することを見出し本発明を完
成するに至った。本発明の皮膚化粧料の場合、従来の皮
膚化粧料のごとく前記の皮膚湿潤剤、皮膚柔軟剤を多量
に配合する必要がなく、皮膚の正常な生理機能が妨げら
れる虞れがない。
Therefore, the present inventors, as a result of intensive studies on the action effects of ceramide, glucosylceramide, galactosylceramide and low molecular weight acidic mucopolysaccharides and salts thereof on human skin, as a result of these specific ceramides and low molecular weight acidic When mucopolysaccharides and / or salts thereof are simultaneously mixed in a cosmetic base and applied to the skin, they show a strong affinity for the surface of the skin and the stratum corneum, which is the outermost layer of the skin,
It was found that they have the effect of densifying their structure and improving aged skin. In addition, low-molecular-weight acidic mucopolysaccharides and salts thereof have a strong affinity for the surface of the skin and the stratum corneum, which is the outermost layer of the skin, and because they are low-molecular substances, they penetrate into the stratum corneum and the moisture inside the skin It exerts the function of regulating the function and enhancing the moisturizing function of the skin. The skin cosmetic of the present invention improves dry skin by enhancing the water-retaining function of the skin itself, or keeps the skin in a healthy state to prevent its aging and moisturizes the skin (moist feeling). The present invention has been completed by finding out that it has a beautiful skin effect of imparting flexibility (smoothness), elasticity and luster. In the case of the skin cosmetic of the present invention, it is not necessary to add a large amount of the above-mentioned skin moisturizer and skin softener unlike the conventional skin cosmetics, and there is no fear that the normal physiological function of the skin will be disturbed.

(発明の目的) 即ち、本発明の目的は、荒肌改善効果、角質改善効果、
保湿効果等の皮膚老化防止効果と美肌効果に優れた皮膚
化粧料を提供することにある。
(Object of invention) That is, the object of the present invention is to improve rough skin, improve keratin,
It is intended to provide a skin cosmetic having excellent skin aging prevention effects such as a moisturizing effect and a beautiful skin effect.

(発明の構成) 本発明は、セラミド、グルコシルセラミド、ガラクトシ
ルセラミドの少なくとも一種と、低分子量の酸性ムコ多
糖類及びその塩からなる群から選択された少なくとも一
種とを配合してなる皮膚化粧料に関するものである。
(Structure of the Invention) The present invention relates to a skin cosmetic composition containing at least one selected from the group consisting of ceramide, glucosylceramide, and galactosylceramide, and at least one selected from the group consisting of low molecular weight acidic mucopolysaccharides and salts thereof. It is a thing.

(構成の具体的な説明) 本発明に用いるセラミド、グルコシルセラミド、ガラク
トシルセラミドは、人、豚、牛、馬、羊などの哺乳動物
の表皮に微量存在する化合物であって(バイオケミスト
リー、アンド、フィジオロジー、オブ、ザ、スキン、第
363頁〜第381頁、Biochemistry and Physiology of the
Skin,Oxford University Press,Inc.1983 New York,ジ
ャーナル、オブ、リピッド、リサーチ 第24巻 1983等
を参照)、これらの動物表皮より通常の抽出方法にて得
ることが可能である。本発明においては、特開昭61−27
1205号公報や生化学実験書(脂質の生化学、生化学実験
講座、第3巻、20〜21頁、1974年、日本生化学会編、東
京化学同人)に記載されている製造方法により得られる
セラミド、グルコシルセラミド、ガラクトシルセラミド
を用いることができる。ここでセラミドは、N−アシル
スフィンゴシン、N−(α−ヒドロキシアシル)‐フィ
トスフィン ゴシン、N−アシルフィトスフィンゴシン
などの混合物である。また、グルコシルセラミドは主に
N−アシルグルコシルスフィンゴシン、N−(α−ヒド
ロキシアシル)−グルコシルフィトスフィゴシン、N−
(α−ヒドロキシアシル)−グルコルスフィンゴシン、
N−(アシル−ω−ヒドロキシアシル)グルコシルフィ
トスフィンゴシンなどの混合物である。ガラクトシルセ
ラミドは主にN−アシルガラクトシルスフィンゴシン、
N−(α−ヒドロキシアシル)−ガラクトシルフィトス
フンゴシン、N−(α−ヒドロキシアシル)−ガラトシ
ルスフィンゴシンなどの混合物である。
(Specific Description of Configuration) Ceramide, glucosylceramide, and galactosylceramide used in the present invention are compounds that are present in trace amounts in the epidermis of mammals such as humans, pigs, cows, horses, and sheep (Biochemistry, And, Physiology, Of, The, Skin, No.
Pages 363-381, Biochemistry and Physiology of the
Skin, Oxford University Press, Inc. 1983 New York, Journal, Ov, Lipid, Research Vol. 24, 1983, etc.), and can be obtained from these animal epidermis by a conventional extraction method. In the present invention, JP-A-61-27
Obtained by the production method described in No. 1205 bulletin and biochemistry experiment manual (lipid biochemistry, biochemistry experiment course, Volume 3, pages 20 to 21, 1974, edited by the Biochemical Society of Japan, Tokyo Kagaku Dojin). Ceramide, glucosylceramide and galactosylceramide can be used. Here, the ceramide is a mixture of N-acyl sphingosine, N- (α-hydroxyacyl) -phytosphingosine, N-acyl phytosphingosine and the like. Further, glucosylceramide is mainly N-acylglucosylsphingosine, N- (α-hydroxyacyl) -glucosylphytosphingosine, N-
(Α-hydroxyacyl) -glucolsphingosine,
A mixture of N- (acyl-ω-hydroxyacyl) glucosylphytosphingosine and the like. Galactosylceramide is mainly N-acylgalactosylsphingosine,
It is a mixture of N- (α-hydroxyacyl) -galactosylphytosfungosin, N- (α-hydroxyacyl) -galatosylsphingosine and the like.

本発明に用いる酸性ムコ多糖類としては、ヒアルロン
酸、デルマタン硫酸、コンドロイチン4硫酸、コンドロ
イチン6硫酸、ヘパリン、ヘパラン硫酸等が使用可能で
あり、それらはいずれもは公知の物質であって、軟骨、
関節、眼球、皮膚その他の結合組織に基質成分となっ
て、蛋白質と結合して動物体内に広く分布している。
As the acidic mucopolysaccharide used in the present invention, hyaluronic acid, dermatan sulfate, chondroitin 4 sulfate, chondroitin 6 sulfate, heparin, heparan sulfate and the like can be used, and they are all known substances, cartilage,
It becomes a matrix component in joints, eyes, skin, and other connective tissues, binds to proteins, and is widely distributed in the animal body.

本発明に用いる酸性ムコ多糖の分子量は、ヒアルロン酸
が1,000〜9,000、デマタン硫酸、コンドロイチン4硫
酸、コンドロイチン6硫酸が1,000〜9,000、ヘパリン、
ヘパラン硫酸が1,000〜6,000のものが好適である。
The molecular weight of the acidic mucopolysaccharide used in the present invention is 1,000 to 9,000 for hyaluronic acid, 1,000 to 9,000 for dematan sulfate, chondroitin 4-sulfate, and chondroitin 6-sulfate, heparin,
Heparan sulfate having 1,000 to 6,000 is preferable.

本発明に用いる酸性ムコ多糖類の塩としては、前記ムコ
多糖類のリチウム塩、ナトリウム塩、カリウム塩などの
アルカリ金属塩、マグネシウム塩、カルシウム塩などの
アルカリ土類金属塩、アンモニウム塩、トリエタノール
アミン塩、ジイソプロパノールアミン塩等のアルカノー
ルアミン塩、リジン塩、アルギニン塩、ヒスチジン塩等
の塩基性アミノ酸塩が好ましいものとして挙げられる。
また、これらの酸性ムコ多糖類は遊離状の酸としても使
用できる。
Examples of the salt of the acidic mucopolysaccharide used in the present invention include lithium metal salts of the mucopolysaccharide, sodium salts, alkali metal salts such as potassium salts, alkaline earth metal salts such as magnesium salts and calcium salts, ammonium salts, triethanol. Preferred are alkanolamine salts such as amine salts and diisopropanolamine salts, and basic amino acid salts such as lysine salts, arginine salts and histidine salts.
Further, these acidic mucopolysaccharides can also be used as a free acid.

本発明に用いる低分子量の酸性ムコ多糖類及びその塩
は、下記の如くして得ることができる。
The low molecular weight acidic mucopolysaccharides and salts thereof used in the present invention can be obtained as follows.

(1)低分子量ヒアルロン酸及びその塩 平均分子量が100万の市販されているヒアルロン酸5g
を、100mlの0.02Nの塩酸水溶液に分散溶解し、pH=2〜
3に調整して充分に攪拌しつつ温浴中で65℃に加温し
た。この加温処理時間を各々120分から200分に変えるこ
とにより、平均分子量が1千から9千のヒアルロン酸を
得ることができる。
(1) Low molecular weight hyaluronic acid and its salt 5 g of commercially available hyaluronic acid having an average molecular weight of 1 million
Is dispersed and dissolved in 100 ml of 0.02N hydrochloric acid aqueous solution, and the pH is 2 to 2.
It was adjusted to 3 and heated to 65 ° C. in a warm bath with sufficient stirring. By changing the heating treatment time from 120 minutes to 200 minutes, hyaluronic acid having an average molecular weight of 1,000 to 9,000 can be obtained.

次いて、N−苛性ソーダで中和した後、該溶液を室温ま
で冷却し、エタノール3倍容を加えて得られる沈澱物を
エタノールで洗浄した後、乾かして低分子ヒアルロン酸
ナトリウム塩の粉末を得た。また、この低分子ヒアルロ
ン酸ナトリウム塩を酸で処理して遊離のヒアルロン酸と
し、次にこれを他の塩基性物質で処理して、例えば、カ
リウム塩、トリエタノールアミノ塩、L−アルギニン塩
等の塩類を調製した。
Next, after neutralizing with N-caustic soda, the solution was cooled to room temperature, 3 times volume of ethanol was added, the precipitate obtained was washed with ethanol, and then dried to obtain a powder of low molecular weight hyaluronic acid sodium salt. It was Further, this low-molecular-weight hyaluronic acid sodium salt is treated with an acid to give free hyaluronic acid, which is then treated with another basic substance, for example, potassium salt, triethanolamino salt, L-arginine salt, etc. Was prepared.

(2)低分子量コンドロイチン4硫酸及びその塩等 平均分子量が3万の市販されているコンドロイチン4硫
酸ナトリウム5gを50mlの水に溶かし、アンバーライトIR
−120(H型)のレジンカラムに通して得られる流出液
を充分に攪拌しつつ、温浴中で75℃に加温した。この加
温処理時間を各々120分から200分に変えることにより、
平均分子量が1,000〜9,000のコンドロイチン4硫酸を得
ることができる。次いて、N−苛性ソーダで中和する。
該溶液を室温まで冷却後、エタノール3倍容を加えて得
られる沈澱物を遠心分離し、エタノールで洗滌した後、
乾燥してコンドロイチン4硫酸ナトリウム塩の粉末を得
た。次いて、このコンドロンチン4硫酸ナトリウム塩を
酸で処理して遊離のコンドロイチン4硫酸とし、次にこ
れを他の塩基性物質で処理して、例えば、カリウム塩、
トリエタノールアミン塩、L−アルギニン塩等の塩類を
調製した。
(2) Low molecular weight chondroitin tetrasulfate and its salt, etc. 5 g of commercially available sodium chondroitin tetrasulfate having an average molecular weight of 30,000 was dissolved in 50 ml of water, and Amberlite IR was used.
The effluent obtained by passing through a −120 (H type) resin column was heated to 75 ° C. in a warm bath while being sufficiently stirred. By changing the heating treatment time from 120 minutes to 200 minutes,
Chondroitin tetrasulfate having an average molecular weight of 1,000 to 9,000 can be obtained. Next, it is neutralized with N-caustic soda.
After the solution was cooled to room temperature, 3 times volume of ethanol was added and the obtained precipitate was centrifuged and washed with ethanol.
After drying, powder of chondroitin tetrasulfate sodium salt was obtained. Next, this chondrontin tetrasulfate sodium salt is treated with an acid to give free chondroitin tetrasulfate, which is then treated with another basic substance such as potassium salt,
Salts such as triethanolamine salt and L-arginine salt were prepared.

また、低分子量コンドロイチン6硫酸、低分子量デルマ
タン硫酸、低分子量ヘパリン、低分子量ヘパラン硫酸等
についても、上記コンドロイチン4硫酸の例と同様の処
理により、遊離状或いはそれぞれの塩類を調製した。
Further, low-molecular-weight chondroitin 6-sulfate, low-molecular-weight dermatan sulfate, low-molecular-weight heparin, low-molecular-weight heparan sulfate, etc. were prepared in free form or their respective salts by the same treatment as in the above example of chondroitin 4-sulfate.

尚、各処理時間により得られた酸性ムコ多糖類の平均分
子量の測定方法は、ソモギー−ネルソン(Somogyi−Nel
son)法を用いた。
The method for measuring the average molecular weight of the acidic mucopolysaccharide obtained by each treatment time was Somogyi-Nelson (Somogyi-Nelson).
son) method was used.

セラミド、グルコシルセラミド、ガラクトシルセラミド
の配合量は皮膚化粧料(組成物)の総量を基準として0.
01〜3.0重量%(以下、Wt%と略記する)の範囲が好適
である。低分子量の酸性ムコ多糖類及びその塩類の配合
量は皮膚化粧料の総量を基準として0.01〜3.0Wt%の範
囲が好適である。ここで、両成分の配合量がそれぞれ0.
01Wt%未満では効果が充分に達成されず、一方3.0Wt%
を超えてもその増加分に見合った効果の向上は望めな
い。
The blending amount of ceramide, glucosylceramide, and galactosylceramide is 0 based on the total amount of the skin cosmetic (composition).
The range of 01 to 3.0% by weight (hereinafter abbreviated as Wt%) is preferable. The content of the low molecular weight acidic mucopolysaccharide and its salts is preferably 0.01 to 3.0 Wt% based on the total amount of the skin cosmetic. Here, the blending amount of both components is 0.
If less than 01Wt%, the effect is not fully achieved, while 3.0Wt%
Even if it exceeds, the improvement of the effect commensurate with the increase cannot be expected.

本発明の皮膚化粧料は、例えばローション類、乳液類、
クリーム類、パック類等に適用することができる。
The skin cosmetics of the present invention include, for example, lotions, emulsions,
It can be applied to creams, packs and the like.

尚、本発明の皮膚化粧料には上記の他に色素、香料、防
腐剤、界面活性剤、顔料、抗酸化剤等を本発明の目的を
達成する範囲内で適宜配合することができる。
In addition to the above, a colorant, a fragrance, an antiseptic, a surfactant, a pigment, an antioxidant and the like can be appropriately added to the skin cosmetic of the present invention within the range where the object of the present invention is achieved.

また、本発明の皮膚化粧料の皮膚老化防止効果を評価す
るために用いた荒肌改善効果試験、角質改善効果試験、
保湿効果試験(TWL値低減率)、美肌効果試験(官能テ
スト)は下記の通りである。
Further, the rough skin improving effect test, which was used to evaluate the skin aging preventing effect of the skin cosmetics of the present invention, the keratin improving effect test,
The moisturizing effect test (TWL value reduction rate) and the skin beautifying effect test (sensory test) are as follows.

(1)荒肌改善効果試験 荒れ肌、乾燥皮膚及び老人性乾皮症状を訴える中高年被
験者20名の下脚を対象として4週間連続塗布効果を調べ
た。被験者の左側下脚試験部位に1日1回約1gの試料を
塗布し、試験開始前及び終了後の皮膚の状態を下記の判
定基準により肉眼判定した。右側下脚は試料を塗布せず
対照とした。
(1) Rough skin improving effect test The lower leg of 20 middle-aged and elderly subjects complaining of rough skin, dry skin, and senile dry skin symptoms was tested for the effect of continuous application for 4 weeks. About 1 g of the sample was applied to the left lower leg test site of the test subject once a day, and the condition of the skin before and after the start of the test was visually judged by the following criteria. The lower right leg was not coated with the sample and served as a control.

試験前後の試験部位と対照部位の判定結果を比較し、皮
膚乾燥度が2段階以上改善された場合(例えば、+→
−、++→±)を有効、1段階改善された場合をやや有
効、変化がなかった場合を無効とした。試験結果は有
効、やや有効となった被験者の人数で示した。
If the skin dryness is improved by two or more levels by comparing the judgment results of the test site before and after the test and the control site (for example, + →
−, ++ → ±) is valid, 1 is slightly improved when it is improved, and is invalid when there is no change. The test results were shown by the number of subjects who were valid or slightly valid.

(2)角質層改善効果試験 前述の荒肌改善効果試験開始前及び終了後の被験者皮膚
にスコッチテープ(ニチバンメンディングテープ)を接
着し、これを剥離した時テープに付着した角質細胞の状
態を走査型電子顕微鏡によって詳細に調べ、下記の基準
によって皮膚角質細胞抗剥離性を解析し、角質層改善効
果(角質細胞抗剥離性増大効果)を求めた。
(2) Stratum corneum improvement effect test Scotch tape (Nichiban Mending Tape) was adhered to the subject's skin before and after the rough skin improvement effect test described above, and when this was peeled off, the state of the corneocytes adhering to the tape was confirmed. It was examined in detail by a scanning electron microscope, the skin keratinocyte anti-peeling property was analyzed according to the following criteria, and the effect of improving the stratum corneum (horny cell anti-peeling property increasing effect) was determined.

評価は、4週間連続塗布後の試験部位の評価点と対照部
位のそれとの差が2点以上の場合を有効、1点の場合を
やや有効、0点の場合を無効とした。試験結果は、20人
中有効、やや有効となった被験者の人数で示した。
In the evaluation, when the difference between the evaluation point of the test site and that of the control site after continuous application for 4 weeks was 2 points or more, the case of 1 point was evaluated as valid, and the case of 0 point was evaluated as invalid. The test results are shown by the number of valid and moderately effective subjects out of 20 persons.

(3)保湿効果試験(TWL値低減率) 前述の荒肌改善効果試験開始前及び終了後の被験者皮膚
を対象として4週間連続塗布前及び塗布後のTWL値及びT
WL値の低減率(水分保持機能亢進効果)を下記の如く算
出して、保湿効果を調べた。
(3) Moisturizing effect test (TWL value reduction rate) TWL value and T before and after continuous application for 4 weeks on the subject's skin before and after the rough skin improving effect test
The moisturizing effect was investigated by calculating the reduction rate of the WL value (water retaining function enhancing effect) as follows.

TWL値 密閉した表皮上の空気の一定時間内の湿度変化を電気抵
抗にて測定する方法を用いた。
TWL value The method of measuring the humidity change of the air on the sealed epidermis within a fixed time by electric resistance was used.

即ち、被試験者の皮表を測定用セルで密閉し、セルに強
制乾燥した空気を通気してセル内を乾燥空気で充分置換
した後、乾燥空気の通気を停止してその時点でのセル内
の相対湿度RHs(%)を求め、次いで10分間放置して再
びセル内の相対湿度RH10(%)を測定し、この時の湿度
変化から下記の式によりTWL値(mg/cm2/hr)を算出し
た。
That is, the skin surface of the test subject is sealed with a measurement cell, and after forcedly drying air through the cell to sufficiently replace the inside of the cell with dry air, the ventilation of the dry air is stopped and the cell at that time is stopped. Calculate the relative humidity RHs (%) in the cell, then leave it for 10 minutes and measure the relative humidity RH 10 (%) in the cell again. From the change in humidity at this time, the TWL value (mg / cm 2 / hr) was calculated.

但し、Dt:測定温度下(t℃)での空気中の飽和水蒸気
の密度(mg/) V:セルの容積() S:測定面積(cm2) TWL値の低減率 TWL値の低減率は、試料塗布前後のTWL値、TWLTA及びTWL
Bを下記の式に代入して算出した。
However, Dt: density of saturated steam in air at measurement temperature (t ° C) (mg /) V: cell volume () S: measurement area (cm 2 ) TWL value reduction rate TWL value reduction rate is , TWL value before and after sample application, TWLT A and TWL
It was calculated by substituting B into the following formula.

TWL値低減率=(1−TWLB/TWLA)×100(%) TWLA:試料塗布前のTWL値 TWLB:試料塗布後のTWL値 TWL値の低減率が20%以上の場合を「有効」、低減率が2
0%未満の場合を「無効」とした。試験結果は、20人中
の「有効」であった被験者の人数で表示した。
TWL value reduction rate = (1-TWL B / TWL A ) × 100 (%) TWL A : TWL value before sample application TWL B : TWL value after sample application When the TWL value reduction rate is 20% or more, Effective ”, reduction rate is 2
The case of less than 0% was defined as "invalid". The test results were displayed by the number of subjects who were “effective” in 20 persons.

(4)美肌効果試験(実用テスト) 荒れ肌、乾燥肌及び老人性乾皮症状等を訴える中高年女
子被験者20人が試料を1日2回(朝・夕)連続3ケ月間
使用後の効果を評価した。試験結果は、皮膚の湿潤性、
平滑性、弾力性の各項目に対して、皮膚に潤いが生じ
た、皮膚が滑らかになった、皮膚に張りが生じたと回答
した人数で示した。
(4) Skin beautification test (practical test) Twenty middle-aged female subjects complaining rough skin, dry skin, and senile psoriasis, etc. evaluated the effect after using the sample twice a day (morning and evening) for three consecutive months. did. The test results are the wettability of the skin,
For each item of smoothness and elasticity, the number of people who responded that the skin was moisturized, the skin was smooth, and the skin was taut.

比較例1〜9、実施例1〜12 〔二層型スキンローション〕 下記の組成の如く、二層型スキンローション基剤にセラ
ミド(以下、Cerと略記する)、グルコシルセラミド
(以下、GluCと略記する)、ガラクトシルセラミド(以
下、GalCと略記する)と、分子量4800と分子量55,000の
ヒアルロン酸(以下、HAと略記する)、分子量4,800と
分子量48,000のヒアルロン酸ナトリウム(以下、HANと
略記する)、分子量6,500をデルマタン硫酸(以下、DS
と略記する)、分子量7,000のデルマタン硫酸カリウム
(以下、DSKと略記する)、分子量4,600のコンドロイチ
ン4硫酸(以下、C4Sと略記する)、分子量5,000のコン
ドロイチン6硫酸(以下、C6Sと略記する)、分子量5,0
00のコンドロイチン4硫酸L−リジン(以下、C4SLと略
記する)、分子量4,300のヘパリン(以下、Hepと略記す
る)、分子量5,400のヘパラン硫酸(以下、HSと略記す
る)などの酸性ムコ多糖類等とをそれぞれ第1、2表に
記載の如く配合した各試料を調製し、各試験に使用し
た。
Comparative Examples 1 to 9 and Examples 1 to 12 [Bilayer Skin Lotion] A bilayer skin lotion base having a ceramide (hereinafter abbreviated as Cer) and glucosyl ceramide (hereinafter abbreviated as GluC) as shown in the following compositions. ), Galactosylceramide (hereinafter abbreviated as GalC), hyaluronic acid having a molecular weight of 4800 and 55,000 (hereinafter abbreviated as HA), sodium hyaluronate having a molecular weight of 4,800 and 48,000 (hereinafter abbreviated as HAN), Dermatan sulfate (hereinafter referred to as DS
Abundant potassium dermatan sulfate (hereinafter abbreviated as DSK), molecular weight 4,600 chondroitin 4-sulfate (hereinafter abbreviated as C4S), molecular weight 5,000 chondroitin 6-sulfate (hereinafter abbreviated as C6S), Molecular weight 5,0
Acid mucopolysaccharides such as 00 chondroitin 4-sulfate L-lysine (hereinafter abbreviated as C4SL), heparin having a molecular weight of 4,300 (hereinafter abbreviated as Hep), heparan sulfate having a molecular weight of 5,400 (hereinafter abbreviated as HS), etc. Each sample was prepared by blending and as shown in Tables 1 and 2 and used in each test.

(1)組成 (2)調製法 (C)成分のセラミド類を予め(A)成分中に、 (D)成分の酸性ムコ多糖類等を(B)成分中に溶解し
た後、(A)成分と(B)成分を各々80℃に加温溶解し
たものを混合した。次いで攪拌しつつ30℃迄冷却して各
ローションを調製した。
(1) Composition (2) Preparation method The ceramides as the component (C) are dissolved in the component (A) in advance, and the acidic mucopolysaccharides as the component (D) are dissolved in the component (B), and then the components (A) and (B) are added. Each of the components was dissolved by heating at 80 ° C. and mixed. Then, each lotion was prepared by cooling to 30 ° C. with stirring.

(3)特性 各二層型スキンローションの諸試験を実施した結果を第
1表右欄に記載した。
(3) Properties The results of various tests of each two-layer type skin lotion are shown in the right column of Table 1.

比較例1〜9のセラミド類或いは酸性ムコ多糖類を単独
配合した化粧料と比較して、両成分を同時に配合した実
施例1〜12の本発明の皮膚化粧料は諸試験の全てに亘っ
て良好なる結果が認められた。
Compared with the cosmetics in which the ceramides or acidic mucopolysaccharides were individually blended in Comparative Examples 1 to 9, the skin cosmetics of the present invention in Examples 1 to 12 in which both components were blended at the same time covered all of the tests. Good results were observed.

実施例13〜25、比較例10〜20 〔スキンクリーム〕 実験例1と同様に、下記の組成にて各々のスキンクリー
ムを調製し、諸試験を実施した結果を第3、4表に示し
た。
Examples 13 to 25, Comparative Examples 10 to 20 [Skin Cream] Similar to Experimental Example 1, each skin cream was prepared with the following composition and various tests were carried out. The results are shown in Tables 3 and 4. .

(1)組成 (2)調製法 (C)成分のセラミド類を予め(A)成分中に、 (D)成分の酸性ムコ多糖類等を(B)成分中に溶解し
た後、(A)成分と(B)成分を各々80℃に加温溶解し
たものを混合した。次いで攪拌しつつ30℃まで冷却して
各スキンクリームを調製した。
(1) Composition (2) Preparation method The ceramides as the component (C) are dissolved in the component (A) in advance, and the acidic mucopolysaccharides as the component (D) are dissolved in the component (B), and then the components (A) and (B) are added. Each of the components was dissolved by heating at 80 ° C. and mixed. Then, each skin cream was prepared by cooling to 30 ° C. with stirring.

(3)特性 第3、4表に示す如く、本発明の皮膚化粧料である実施
例13〜26のスキンクリームは、比較例10〜18と比較して
諸特性の全てに亘って優れていることは明らかであり、
配合特性に於いても異常は認められなかった。なお、比
較例19として、セラミド0.2wt%、高分子量ヒアルロン
酸ナトリウム(平均分子量600万)0.3wt%を含有させた
クリーム、及び比較例20として、ラムノリピド0.2wt
%、低分子量ヒアルロン酸ナトリウム(平均分子量480
0)0.3wt%を含有させたクリームについて、荒れ肌、乾
燥肌及び老人性乾皮症状を訴える中高年女子被験者20名
に対し、試料を1日3回(朝・昼・夕)連続4週間使用
させ、短期連用試験により弾力性に関して評価した。そ
の結果、皮膚に張りが生じたと回答した人数は、比較例
19では9名、比較例20では5名であった。一方、実施例
25として、セラミド0.2wt%、低分子量ヒアルロン酸ナ
トリウム(平均分子量4800)0.3wt%を含有させたクリ
ームについて、同様に弾力性に関して評価したところ、
皮膚に張りが生じたと回答した人数は14名であった。
(3) Characteristics As shown in Tables 3 and 4, the skin creams of Examples 13 to 26, which are the skin cosmetics of the present invention, are excellent in all of the characteristics as compared with Comparative Examples 10 to 18. Is clear,
No abnormality was found in the compounding characteristics. As Comparative Example 19, 0.2 wt% ceramide, cream containing 0.3 wt% of high molecular weight sodium hyaluronate (average molecular weight 6 million), and as Comparative Example 20, rhamnolipid 0.2 wt%
%, Low molecular weight sodium hyaluronate (average molecular weight 480
0) About the cream containing 0.3 wt%, the sample was used for 20 consecutive middle and old aged female subjects who complained of rough skin, dry skin and senile dry skin symptoms, three times a day (morning, noon and evening) for 4 consecutive weeks. The elasticity was evaluated by a short-term continuous test. As a result, the number of people
There were 9 in 19 and 5 in Comparative Example 20. On the other hand, Example
As 25, a cream containing 0.2 wt% of ceramide and 0.3 wt% of low molecular weight sodium hyaluronate (average molecular weight 4800) was similarly evaluated for elasticity,
The number of people who responded that the skin had become ten was 14 people.

(発明の効果) 以上記載の如く、本発明は、皮膚機能を亢進し、皮膚の
老化防止に顕著な効果を発現する優れた有用なる皮膚化
粧料を提供することが明らかである。
(Effects of the Invention) As described above, it is apparent that the present invention provides an excellent and useful skin cosmetic that enhances skin function and exerts a remarkable effect in preventing skin aging.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】セラミド、グルコシルセラミド、ガラクト
シルセラミドの少なくとも一種と、平均分子量1,000〜
9,000のヒアルロン酸、平均分子量1,000〜9,000のコン
ドロイチン硫酸、デルマタン硫酸、平均分子量1,000〜
6,000のヘパリン及びヘパラン硫酸及びその塩の低分子
量の酸性ムコ多糖類の群より選択された少なくとも一種
とを配合してなる皮膚化粧料。
1. At least one of ceramide, glucosylceramide, and galactosylceramide, and an average molecular weight of 1,000 to
9,000 hyaluronic acid, average molecular weight 1,000 to 9,000 chondroitin sulfate, dermatan sulfate, average molecular weight 1,000 to
A skin cosmetic comprising 6,000 heparin and at least one selected from the group of low molecular weight acidic mucopolysaccharides of heparan sulfate and its salts.
JP62176904A 1987-07-15 1987-07-15 Skin cosmetics Expired - Fee Related JPH06104620B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP62176904A JPH06104620B2 (en) 1987-07-15 1987-07-15 Skin cosmetics

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP62176904A JPH06104620B2 (en) 1987-07-15 1987-07-15 Skin cosmetics

Publications (2)

Publication Number Publication Date
JPS6422809A JPS6422809A (en) 1989-01-25
JPH06104620B2 true JPH06104620B2 (en) 1994-12-21

Family

ID=16021786

Family Applications (1)

Application Number Title Priority Date Filing Date
JP62176904A Expired - Fee Related JPH06104620B2 (en) 1987-07-15 1987-07-15 Skin cosmetics

Country Status (1)

Country Link
JP (1) JPH06104620B2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0696514B2 (en) * 1987-07-15 1994-11-30 鐘紡株式会社 Skin cosmetics
JPH01272511A (en) * 1988-04-21 1989-10-31 Tokyo Sankei Kagaku:Kk Additive for cosmetic
JPH0647528B2 (en) * 1990-03-07 1994-06-22 キユーピー株式会社 Cosmetics
CA2099188C (en) * 1992-07-24 2005-12-13 Paul A. Bowser Use of a cosmetic composition
FR2725622A1 (en) * 1994-10-14 1996-04-19 Fabre Pierre Dermo Cosmetique CERAMIDE GREFFEE ANTI-ELASTASE
US5996329A (en) * 1998-05-15 1999-12-07 Cardenas; Curtis E. Multi-axis machining head
FR2825273B1 (en) * 2001-05-29 2006-11-24 Oreal COMPOSITION FOR THE TREATMENT OF SKIN SIGNS OF AGING
JP2003160462A (en) * 2001-11-21 2003-06-03 Pola Chem Ind Inc Functional skin care preparation having barrier function
KR101449687B1 (en) * 2008-03-13 2014-10-14 주식회사 바이오랜드 Anti-aging Composition for external Use comprising low and high molecular weight hyaluronic acids and the polysaccharides extracted from roots of Ulmus davidiana var. japonica
JP2009234957A (en) * 2008-03-26 2009-10-15 Japan Medic Kk External medicine for skin
DK2679278T3 (en) * 2008-11-20 2017-12-11 Laboratori Derivati Organici S P A Dermatological compositions comprising heparan sulfate
JP5888563B2 (en) * 2013-10-30 2016-03-22 株式会社東洋新薬 Moisturizer, rough skin improving agent, stratum corneum moisture increasing agent, blood flow improving agent and skin dullness, bear or gloss improving agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS559046A (en) * 1978-07-05 1980-01-22 Otsuka Pharmaceut Factory Inc Composition for skin application
JPS5939338A (en) * 1982-08-30 1984-03-03 Shiseido Co Ltd Emulsified composition
JPS59219209A (en) * 1983-05-28 1984-12-10 Kanebo Ltd Skin cosmetic
JPH0657651B2 (en) * 1985-05-15 1994-08-03 サンスタ−株式会社 Cosmetic composition
JPS6245336A (en) * 1985-08-21 1987-02-27 Toyo Biyuut Kk Emulsified composition
JPH0696514B2 (en) * 1987-07-15 1994-11-30 鐘紡株式会社 Skin cosmetics

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
フレグランスジャーナル臨時増刊No.4(1983)P.102〜108

Also Published As

Publication number Publication date
JPS6422809A (en) 1989-01-25

Similar Documents

Publication Publication Date Title
JPH06104620B2 (en) Skin cosmetics
JPS61271205A (en) Skin cosmetic
JP3922311B2 (en) Skin aging prevention cosmetics
JPH0696514B2 (en) Skin cosmetics
JPS63150209A (en) Skin cosmetic
JP2511820B2 (en) Skin cosmetics
JPH07187987A (en) Skin cosmetic
JPS62209010A (en) Cosmetic
JPS62175415A (en) Skin cosmetic
JP2611956B2 (en) Skin cosmetics
JPH0366604A (en) Dermal cosmetic
JP2931083B2 (en) Skin cosmetics
JP2004075635A (en) Moisturizing agent and external preparation for skin
JP2553474B2 (en) Skin cosmetics
JP2511817B2 (en) Skin cosmetics
JPS62209009A (en) Cosmetic
JPH1036230A (en) Composition for hair cosmetic and hair cosmetic
JPS62249912A (en) Skin cosmetic
JPS62153206A (en) Skin cosmetic
CN115804728B (en) Multi-channel anti-aging composition and preparation method and application thereof
KR960012607B1 (en) Cosmetic composition for dryness prevention of skin
JPS62126106A (en) Skin cosmetic
JPS62298509A (en) Skin cosmetic
JPH09208420A (en) Cosmetic material for skin
JPH0692290B2 (en) Skin cosmetics

Legal Events

Date Code Title Description
S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees